|  |  |  |
| --- | --- | --- |
| Supplemental Table 2.Prior anticancer therapy and prior/relevant medical conditions (full analysis set). | | |
| **Therapy** | **Category** | **Number of Patients**  **(N = 3014)** |
| Previous EGFR-TKI treatment\*, n (%) | Gefitinib | 1722 (57) |
|  | Erlotinib | 904 (30) |
|  | Icotinib | 371 (12) |
|  | Afatinib | 295 (10) |
|  | Other | 64 (2) |
| Previous anticancer treatment, n (%) | Chemotherapy | 1443 (48) |
|  | Radiotherapy | 1129 (37) |
|  | Surgery | 730 (24) |
|  | Antiangiogenic therapy | 128 (4) |
|  | Immunotherapy | 63 (2) |
|  | Other | 83 (3) |
| Time between last anticancer therapy and enrollment, months | Median (range) | 0.5 (0–39) |
| Concomitant medications†, n (%) |  | 2631 (87) |
| Past or current relevant medical history, n (%) | Patients with ≥ 1 condition | 2390 (79) |
|  | Most common conditions‡ |  |
|  | Hypertension | 892 (30) |
|  | Cough | 268 (9) |
|  | Type 2 diabetes mellitus | 267 (9) |
|  | Dyspnea | 146 (5) |
|  | Metastases to bone | 139 (5) |
|  | Back pain | 117 (4) |
|  | Cataract | 116 (4) |
|  | Insomnia | 113 (4) |
|  | Constipation | 101 (3) |
|  | Hypothyroidism | 96 (3) |
|  | Decreased appetite | 94 (3) |
|  | Pleural effusion | 92 (3) |
|  | Cholelithiasis | 91 (3) |
|  | Rash | 90 (3) |
|  | Hyperlipidemia | 89 (3) |
| \* Patients may have received more than one previous EGFR-TKI.  † Concomitant medications are those with a stop date on or after the first dose date of study treatment (and could have started prior to or during treatment).  ‡ Past or current relevant medical history occurring in ≥ 3% of patients. EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor. | | |